



MEDICAL TIPS

TENEBLU Tablets

Issue II, No. 7, 2023

Evaluation of Teneligliptin a DPP4 Inhibitor in Terms of Efficacy and Safety with Respect to QT/QTc Prolongation in Patients with Type II Diabetes Mellitus (T2DM)

Bhosle D, et al. J. Assoc. Physicians India. 2022; 70(5):11-12.

- According to the American Diabetes Association (ADA)-European Association for the study of Diabetes (EASD) joint statement, use of the newer cardio-safe drugs for treatment of T2DM are highly recommended.
- Teneligliptin, which has a low risk of hypoglycemia and weight neutral properties, was studied in Indian T2DM patients for its cardiac safety in terms of QTc prolongation at therapeutic doses.
- Teneligliptin 20 mg once daily as an add-on with other oral hypoglycemic agents (OHAs) was associated with significant reductions in the glycemetic parameters.
- There was no significant change in the QT interval and QTc interval from the baseline to the end of study at 12 weeks.

Teneligliptin is a promising drug that can help patients with T2DM achieve targeted glycemetic control without prolonging the QT/QTc interval.

